Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Nepsone General Information
Nepsone ehf develops preclinical-stage small molecule drugs for skin diseases such as psoriasis, atopic dermatitis, and alopecia areata. Their approach leverages a novel neuroimmunology theory that implicates imbalances in the autonomic nervous system and neuropeptide activity as root causes of these diseases. No clinical results have been reported yet.
Contact Information
Drug Pipeline
Pre-clinical
Key Partnerships
Grant from Tækniþróunarsjóður/Technology Development Fund of Rannís – The Icelandic Centre for Research
Nepsone Funding
No funding data available
To view Nepsone's complete valuation and funding history, request access »